Medicare has expanded coverage for BRACAnalysis CDx for men with prostate cancer who are eligible or may become eligible for treatment with Lynparza (olaparib). BRACAnalysis CDx from Myriad Genetics, Salt Lake City, is the only germline test covered for this indication. “One in six patients with prostate cancer have a hereditary form of the disease and are six times more likely to die from it within 5 years,” says Nicole Lambert, president of Myriad International, Oncology and Women’s Health. “Providers with earlier knowledge of their patient’s germline status can help tailor treatments and can provide eligibility for life-sustaining therapies should they progress to metastasis. Additionally, the information can be provided to the patient’s family members to prevent future cancers.” According to the American Cancer Society, 191,930 new cases of prostate cancer occur every year and approximately 33,330 men will die from the disease this year. In May, the FDA approved the BRACAnalysis CDx test for use as a companion diagnostic tool by healthcare professionals to identify men with metastatic castration-resistant prostate cancer (mCRPC) who are eligible for treatment with Lynparza (olaparib). Lynparza, a nonchemotherapy oral medication, is approved for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. For more information, visit Myriad.